Immunization of mice with recombinant S-adenosyl-l-homocysteine hydrolase protein confers protection against Brucella melitensis infection

FEMS Immunology and Medical Microbiology

Volumn 61, Issue 2, 2011, Pages 159-167

  Yang, Yanling ^a,b   Yin, Jigang ^a   Guo, Dejun ^c   Lang, Xulong ^b   Wang, Xinglong ^a,b  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

Brucellosis; Immunogenic proteins; Immunoproteomics; Subunit vaccine

Indexed keywords

ADENOSYLHOMOCYSTEINASE; GAMMA INTERFERON; INTERLEUKIN 2; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BRUCELLA MELITENSIS; BRUCELLOSIS; ESCHERICHIA COLI; EXTRACT; FEMALE; GENE; IMMUNIZATION; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOGENICITY; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCREENING; TWO DIMENSIONAL ELECTROPHORESIS;

ADENOSYLHOMOCYSTEINASE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNIZATION; IMMUNOBLOTTING; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SPLEEN;

EID: 79951474768     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00758.x     Document Type: Article

References (41)

1. Adone R, Francia M & Ciuchini F (2008) Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections. Vaccine 26: 4913-4917.
2. Al-Mariri A (2010) Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine 28: 1766-1770.
3. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K & Letesson JJ (2001a) Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 69: 4816-4822.
4. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, Walravens K & Letesson JJ (2001b) Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect Immun 69: 6264-6270.
5. Altindis E, Tefon BE, Yildirim V, Ozcengiz E, Becher D, Hecker M & Ozcengiz G (2009) Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins. Vaccine 27: 542-548.
6. Andrews E, Salgado P, Folch H & Onate A (2006) Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase: II. Induction of specific CD8+ cytotoxic lymphocytes and sensitized CD4+ IFN-gamma-producing cell. Microbiol Immunol 50: 389-393.
7. Blasco JM (1997) A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 31: 275-283.
8. Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA & Baldi PC (2004) Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clin Diagn Lab Immun 11: 111-114.
9. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA & Giambartolomei GH (2005) Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 73: 8079-8088.
10. Chen Z, Peng B, Wang S & Peng X (2004) Rapid screening of highly efficient vaccine candidates by immunoproteomics. Proteomics 4: 3203-3213.
11. Cloeckaert A, Verger JM, Grayon M, Paquet JY, Garin-Bastuji B, Foster G & Godfroid J (2001) Classification of Brucella spp. isolated from marine mammals by DNA polymorphism at the omp2 locus. Microbes Infect 3: 729-738.
12. Connolly JP, Comerci D, Alefantis TG, Walz A, Quan M, Chafin R, Grewal P, Mujer CV, Ugalde RA & DelVecchio VG (2006) Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development. Proteomics 6: 3767-3780.
13. Corbel MJ (1997) Brucellosis: an overview. Emerg Infect Dis 3: 213-221.
14. De La Haba G & Cantoni GL (1959) The enzymatic synthesis of S-adenosyl-l-homocysteine from adenosine and homocysteine. J Biol Chem 234: 603-608.
15. DelVecchio VG, Kapatral V, Redkar RJ et al. (2002) The genome sequence of the facultative intracellular pathogen Brucella melitensis. P Natl Acad Sci USA 99: 443-448.
16. Duerre JA (1962) Preparation and properties of S-adenosyl-l-homocysteine, S-adenosyl-l-homocysteine sulfoxide and S-ribosyl-l-homocysteine. Arch Biochem Biophys 96: 70-76.
17. Eloranta TO, Kajander EO & Raina AM (1976) A new method for the assay of tissue. S-adenosylhomocysteine and S-adenosylmethione. Effect of pyridoxine deficiency on the metabolism of S-adenosylhomocysteine, S-adenosylmethionine and polyamines in rat liver. Biochem J 160: 287-294.
18. Eschenbrenner M, Wagner MA, Horn TA, Kraycer JA, Mujer CV, Hagius S, Elzer P & DelVecchio VG (2002) Comparative proteome analysis of Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16M. J Bacteriol 184: 4962-4970.
19. Eze MO, Yuan L, Crawford RM, Paranavitana CM, Hadfield TL, Bhattacharjee AK, Warren RL & Hoover DL (2000) Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect Immun 68: 257-263.
20. Huang L, Krieg AM, Eller N & Scott DE (1999) Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun 67: 6257-6263.
21. Jahans KL, Foster G & Broughton ES (1997) The characterisation of Brucella strains isolated from marine mammals. Vet Microbiol 57: 373-382.
22. Jennison AV, Raqib R & Verma NK (2006) Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T. World J Gastroentero 12: 6683-6688.
23. Ko J & Splitter GA (2000) Residual virulence of Brucella abortus in the absence of the cytochrome bc(1)complex in a murine model in vitro and in vivo. Microb Pathogenesis 29: 191-200.
24. Lefrancois L & Masopust D (2002) T cell immunity in lymphoid and non-lymphoid tissues. Curr Opin Immunol 14: 503-508.
25. Murphy EA, Sathiyaseelan J, Parent MA, Zou B & Baldwin CL (2001) Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103: 511-518.
26. Neuhoff V, Arold N, Taube D & Ehrhardt W (1988) Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 9: 255-262.
27. Nielsen K & Duncan JR (1988) Antibody isotype response in adult cattle vaccinated with Brucella abortus S19. Vet Immunol Immunop 19: 205-214.
28. Oliveira SC & Splitter GA (1996) Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14: 959-962.
29. Pakzad I, Rezaee A, Rasaee MJ, Tabbaraee B & Delpisheh A (2009) Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model. Iran J Immunol 6: 12-21.
30. Seleem MN, Boyle SM & Sriranganathan N (2010) Brucellosis: a re-emerging zoonosis. Vet Microbiol 140: 392-398.
31. Sganga MW, Aksamit RR, Cantoni GL & Bauer CE (1992) Mutational and nucleotide sequence analysis of S-adenosyl-l-homocysteine hydrolase from Rhodobacter capsulatus. P Natl Acad Sci USA 89: 6328-6332.
32. Sinha S, Kosalai K, Arora S, Namane A, Sharma P, Gaikwad AN, Brodin P & Cole ST (2005) Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology 151: 2411-2419.
33. Splitter G, Oliveira S, Carey M, Miller C, Ko J & Covert J (1996) T lymphocyte mediated protection against facultative intracellular bacteria. Vet Immunol Immunop 54: 309-319.
34. Stevens MG, Olsen SC, Pugh GW & Palmer MV (1994) Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infect Immun 62: 3206-3212.
35. Tabatabai LB & Pugh GW (1994) Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 12: 919-924.
36. Teixeira-Gomes AP, Cloeckaert A, Bezard G, Bowden RA, Dubray G & Zygmunt MS (1997) Identification and characterization of Brucella ovis immunogenic proteins using two-dimensional electrophoresis and immunoblotting. Electrophoresis 18: 1491-1497.
37. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA & Spitz M (2002) A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 70: 2507-2511.
38. Wagner MA, Eschenbrenner M, Horn TA, Kraycer JA, Mujer CV, Hagius S, Elzer P & DelVecchio VG (2002) Global analysis of the Brucella melitensis proteome: identification of proteins expressed in laboratory-grown culture. Proteomics 2: 1047-1060.
39. Wu QL, Fu YF, Zhou WL et al. (2005) Inhibition of S-adenosyl-l-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther 313: 705-711.
40. Zhan Y & Cheers C (1993) Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 61: 4899-4901.
41. Zhan Y, Liu Z & Cheers C (1996) Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 64: 2782-2786.